Brief: Eyal Rubin Resigns As CFO Of Protalix Biotherapeutics - SEC Filing
April 23 (Reuters) - Protalix Biotherapeutics Inc PBDA.F: PROTALIX BIOTHERAPEUTICS INC - ON APRIL 21 EYAL RUBIN RESIGNS AS CFO OF PROTALIX BIOTHERAPEUTICS - SEC FILING Source text: [ID:n0001558370-25-005275] Further company coverage: PBDA.F ((Reuters.Briefs@thomsonreuters.com))
Recent news on Protalix BioTherapeutics
See all newsIsrael's Protalix Q2 revenue rises on Elfabrio sales, reiterates 2026 outlook
Israel's Protalix Q1 revenue surges on Chiesi milestone
Brief: Protalix BioTherapeutics Q1 EPS USD 0.23
Brief: Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results
Brief: EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio